Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence…

NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…

The pharmaceutical market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has the potential to become lucrative owing to the current lack of…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…

NASH is an increasingly prevalent disease characterized by excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver fibrosis. Ensuing complications can include liver…

Hepatitis B virus (HBV) infection is a major public health burden in China, and chronically infected HBV patients are at a high risk of developing hepatic cirrhosis and hepatocellular carcinoma…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…